Drug Trial Radar · NCT07774611
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Sep 18, 2026
Primary completion
Jun 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, open-label Phase Ib/II study with dose escalation and expansion in Chinese patients with advanced solid tumors consists of Part A (SG1827 plus anti-PD-1/PD-L1) and Part B (SG1827 plus anti-PD-1/PD-L1 and bevacizumab), both evaluating safety, tolerability, PK/PD, immunogenicity, and antitumor efficacy.
Conditions
- Advanced Solid Tumors
Interventions
SG1827Drug
Intravenous infusion, once every three weeks
anti-PD-1/PD-L1 antibodyDrug
Intravenous infusion
bevacizumabDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- AEsTime frame: From first dose until 30 days after last dose of SG1827
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Dongguan People's Hospital
Dongguan, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guanzhou, Guangdong, China · Recruiting
The Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China · Not yet recruiting
Harbin Medical University Cencer Hospital
Haerbin, Heilongjiang, China · Not yet recruiting
The First Affiliated Hospital of Henan Medical University
Xinxiang, Henan, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.